Correspondence

This section is populated with a variety of content produced by HLC.  This includes but is not limited to materials and correspondence that HLC has produced in its communication efforts with Congress on the various issues of interest to our members and their companies as well as affiliated coalitions, campaigns, task force groups as well as documents from testimony before Congress.

May 2025

• HLC joint letter to House Leadership opposing Medicaid cuts in advance of the Floor vote on the Reconciliation Bill
• HLC letter to the MAHA Commission in advance of its “Make our Children Healthy Again Assessment”
• HLC response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
• HLC group letter urging Congress to enact the Ensuring Community Access to Pharmacist Services Act
• HLC joint letter urging Congress to reauthorize the Cybersecurity Information Sharing Act (CISA) of 2015

April 2025

• HLC joint letter to CMS in response to the Marketplace Integrity and Affordability Proposed Rule
• HLC letter endorsing the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act
• HLC joint letter to Congressional Leadership urging them to reject Medicaid funding cuts
• HLC joint letter endorsing S.988, the Medical Supply Chain Resiliency Act
• HLC and Confidentiality Coalition response to House Energy and Commerce Committee Data Privacy Working Group RFI
• HLC support letter for H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act

March 2025

• HLC letter to DEA in response to Telehealth Special Registration proposed rule
• HLC and Confidentiality Coalition Response to RFI on AI
• HLC letter to the House W&M Subcommittee on Health regarding its hearing, “After the Hospital: Ensuring Access to Quality Post-Acute Care”
• HLC and Confidentiality Coalition comments to CMS on the NPRM entitled, “HIPAA Security Rule to Strengthen the Cybersecurity Protected Health Information”

February 2025

• HLC support letter for H.R. 1492, the Ensuring Pathways to Innovative Cures (EPIC) Act
• HLC joint letter to CMS on the CY 2026 Medicare Advantage and Part D Advance Notice
• HLC joint letter urging Congress to reinstitute pre-deductible telehealth coverage for Health Savings Account-eligible plans

January 2025

• HLC Priorities Letter to Congressional Leadership
• HLC group letter to the Trump Administration outlining priorities to improve enrollment data, systems, and processes for eligible populations under 65
• HLC group letter urging Congress to enact financial relief for family caregivers
• HLC response to CMS Contract Year 2026 Medicare Advantage and Part D Proposed Rule

December 2024

• HLC letter to President-elect Trump Transition Team
• HLC EOY Priorities letter to Congress

November 2024

• HLC response to HHS Notice of Benefit and Payment Parameters Proposed Rule for 2026
• HLC joint letter advocating affordability and stability for Medicare Advantage during Open Enrollment
• HLC joint letter in response to the HHS Notice of Benefit and Payment Parameters Proposed Rule for 2026
• HLC joint letter urging Congress to extend critical telehealth flexibilities
• HLC letter urging Congressional action on key end-of-year healthcare priorities

October 2024

• HLC comments on HTI-2 Proposed Rule
• HLC response to Wenstrup RFI

September 2024

• HLC joint letter to sponsors and House Leadership in support of H.R. 8111, “the Medicaid Program Improvement Act”
• HLC letter to the Senate Finance Committee regarding its hearing, “Lowering Health Care Costs for Americans: Understanding the Benefits of the Inflation reduction Act”

August 2024

• HLC comments on FDA Demonstrating Interchangeability Guidance
• HLC response to request for stakeholder input on next-generation Cures Bill

July 2024

• HLC statement for the record to House Veterans Affairs Subcommittee on Disability Assistance and Memorial Affairs in support of H.R.8881, a bill to amend title 38, United States Code, to permanently authorize the performance of Department of Veterans Affairs disability examinations by non-Department physicians pursuant to contracts, and for other purposes
• HLC letter to Senate Committee on Armed Services endorsing the legislative proposal to amend 10 U.S.C. 1094 and grant license reciprocity in any state to certain healthcare professionals providing medical services to members of the Reserve Components
• HLC letter to Senate Veterans Affairs Committee endorsing S. 3979, which amends 38 U.S.C. 5101 to provide license portability for all Department of Veterans Affairs medical disability examiners
• HLC letter to the Cybersecurity and Infrastructure Security Agency (CISA) regarding the proposed rule for implementing the Cyber Incident Reporting for Critical Infrastructure Act (CIRCIA)
• HLC letter endorsing H.R. 7292, the “Health Accelerating Consumers Care by Expediting Self-Scheduling (Access) Act”

June 2024

• HLC letter to the House W&M Subcommittee on Health in advance of its hearing, “Improving Value-Based Care for Patients and Providers”
• HLC joint letter to the House E&C Committee in support of H.R. 7856, the “PREVENT DIABETES Act”
• HLC joint letter responding to the Senate Finance Committee’s Bipartisan Medicare Graduate Medical Education Working Group’s draft policy outline
• HLC joint letter to the Senate Committee on Finance in response to its white paper entitled, “Bolstering Chronic Care through Physician Payment: Current Challenges and Policy Options in Medicare Part B”
• HLC letter to House E&C Subcommittee on Health in advance of its hearing, “Checking-In on CMMI: Assessing the Transition to Value-Based Care”
• HLC stakeholder letter with over 60 signatories to the Senate Committee on the Budget urging the Senate to hotline H.R. 766, the “Dr. Michael C. Burgess Preventive Health Savings Act”
• HLC’s comment on the Senate Finance Committee’s discussion draft proposing a Medicare program to prevent and mitigate chronic drug shortages
• HLC response to the HHS/FTC/DOJ request for information regarding consolidation and the role of private equity in the healthcare sector

May 2024

• HLC letter to the Senate Committee on the Budget urging the Senate to hotline H.R. 766, the “Dr. Michael C. Burgess Preventive Health Savings Act”
• HLC response to the FTC/HHS RFI regarding drug shortages and purchasers’ role in the supply chain
• HLC response to CMS RFI on Medicare Advantage Data
• HLC comment letter supporting the alternations within the drafted 2024-2030 Healthcare IT Strategic Plan
• HLC Memo to the Senate Commerce Committee and House Energy and Commerce Committee staff requesting changes to the American Privacy Rights Act of 2024 to make sure it provides a true national privacy standard for healthcare companies that continues to empower innovation
• HLC letter for the record supporting E&C’s action regarding the expiring telehealth and acute hospital care at home waivers, and requesting a greater extension and expansion of coverage
• HLC letter in advance of the Senate Committee on Finance hearing, “Rural Health Care: Supporting Lives and Improving Communities”
• HLC joint letter to HHS supporting automatic enrollment for eligible individuals into Medicaid and other $0 net-premium plans
• HLC letter to Senate Committee on the Budget in advance of the hearing, “Reducing Paperwork, Cutting Costs: Alleviating Administrative Burdens in Health Care”
• HLC letter ahead of the W&M bill mark-up supporting action regarding the expiring telehealth and acute hospital care at home waivers, and requesting a greater extension and expansion of coverage
• HLC response to Rep. Ami Bera’s RFI regarding the use of AI in the healthcare sector
• HLC Joint Letter to Senate Finance Committee regarding the hearing, “Bolstering Chronic Care through Medicare Physician Payment”
• HLC letter in advance of the Senate HELP Committee Hearing, “What Can Congress Do to Address the Severe Shortage of Minority Health Care Professionals and the Maternal Health Crisis?”
• HLC letter to the Senate Finance Committee in advance of the hearing, “Hacking America’s Heatlh Care: Assessing the Change Healthcare Cyber Attack and What’s Next”
• HLC letter to the House Energy and Commerce Committee’s Oversight and Investigations Subcommittee in advance of the hearing, “Examining the Change Healthcare Cyberattack”

April 2024

• HLC letter to House E&C Subcommittee on Health in advance of their hearing, “Legislative Proposals to Increase Medicaid Access and Improve Program Integrity”
• HLC joint letter to Senate Finance Committee urging the removal of patient cost-sharing obligations from Medicare’s Chronic Care Management code
• HLC joint letter urging CMS not to finalize the price stacking provision in its Medicaid Drug Rebate Program Proposed
• HLC letter to House E&C Subcommittee on Health in advance of their hearing, “Examining Health Sector Cybersecurity in the Wake of the Change Healthcare Attack”
• HLC’s joint letter criticizing CMS’s regulatory overreach regarding the oversight of supplemental Medicaid payment to hospitals
• HLC joint letter endorsing H.R. 7856, the “PREVENT DIABETES Act,” to make the diabetes prevention program available to qualifying beneficiaries both online and in-person
• HLC letter to House E&C Subcommittee on Health hearing on, “Legislative Proposals to Support Patient Access to Telehealth Services”

March 2024

• HLC response to House Ways and Means Committee hearing “Enhancing Access to Care at Home in Rural and Underserved Communities”
• HLC letter to House Leadership in support of H.R. 766, the “Dr. Michael C. Burgess Preventive Health Savings Act” advance of a Floor Vote
• HLC comments on CMS Medicare Prescription Payment Plan Draft Part Two Guidance
• HLC response to House Education and Workforce Committee RFI on ways to build on and strengthen ERISA
• HLC joint letter in response to the CMS 2025 Medicare Advantage Advance Notice
• HLC letter opposing Nevada’s 1332 waiver application to implement a state “public option”
• HLC joint letter endorsing H.R. 7050, the “Substance Use Disorder Workforce Act.”
• HLC joint letters to House leadership and Senate Finance and Budget Committees in support of H.R.766/S.114, the “Preventive Health Savings Act”
• HLC response to the CMS 2025 Medicare Advantage and Part D Advance Notice

February 2024

• HLC joint letter endorsing H.R. 7165/S. 3702, the “Credit for Caring Act”
• HLC letter to House sponsors in support of H.R. 7312, the “Electronic Prescribing for Controlled Substances Act”
• HLC joint letter to congressional leadership urging congress to make current telehealth flexibilities permanent
• HLC joint letter supporting H.R. 1310, the “States Handling Access to Reciprocity for Employment Act”
• HLC joint letter in support of H.R. 633, the “Supporting Patient Education and Knowledge Act” and H.R. 5762, the “Health Communication Access and Resources for Everyone Act”
• HLC joint letter to CMS urging meaningful patient engagement in the implementation of IRA drug pricing provisions
• HLC joint letter supporting H.R. 5829, the Health Care Practitioner Disaster Protection Act.
• HLC letter to the Senate Finance committee in advance of their hearing, “Artificial Intelligence and Health Care: Promise and Pitfalls”
• HLC joint letter to NIST urging them to withdraw the proposed guidance on March-in rights.
• HLC letter to the House W&M committee in advance of their hearing, “Examining Chronic Drug Shortages in the United States.”
• HLC letter to the House Budget Committee in support of H.R. 766, the “Preventive Health Savings Act”
• HLC letter to The National Institute of Standards and Technology (NIST) criticizing the newly published guidance, “Draft Interagency March-In Framework.”
• HLC response to OIG’s solicitation of ideas for updates to AKS safe harbors

January 2024

• HLC letter to the House E&C in advance of their hearing, “Health Care Spending in the United States: Unsustainable for Patients, Employers, and Taxpayers”
• HLC joint letter to CMS supporting provisions to prevent coverage loss and improve data included in its “Enforcement of State Compliance With Reporting and Federal Medicaid Renewal Requirements” interim final rule
• HLC joint letter to congressional leadership on the urgent need to reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA)
• HLC joint letter to CMS supporting continuity of coverage in response to its 2025 Notice of Benefit and Payment Parameters proposed rule
• HLC joint letter to CMS to strengthen, improve, and support Medicare Advantage
• HLC joint letter in support of nutrition language in the Bipartisan Primary Care and Work Force Act
• HLC response to CMS 2025 Medicare Advantage and Part D proposed rule
• HLC response to CMS 2025 Notice of Benefit and Payment Parameters proposed rule

  December 2023

• HLC joint letter to the Department of Commerce requesting an extension to the comment period of the request for information on an interagency march-in rights guidance framework
• HLC letter to the Senate Finance Committee regarding their hearing, “Drug Shortages: Examining Supply Challenges, Impacts, and Policy Solutions from a Federal Health Program Perspective”
• HLC joint letter urging Congress to pass legislation to fix the disparity in the IRA that subjects small molecule medicines to price setting sooner than biologics
• HLC joint letter to CMS requesting the continued publication of Medicaid renewal data past the unwinding period
• HLC joint letters to sponsors and House Budget Committee in support of H.R.766/S.114, the “Preventive Health Savings Act”
• HLC letter to Senate HELP Committee in support of S.2666 the “Electronic Prescribing for Controlled Substances Act” (EPCS 2.0 Act)
• HLC letter to House E&C Committee in advance of their hearing, “Leveraging Agency Expertise to Foster American AI Leadership and Innovation”
• HLC letter to House sponsors in support of H.R. 6205, the Healthcare Workforce Resilience Act
• HLC letter of support for H.R. 618, the “Improving Access to Workers Compensation for Injured Federal Workers Act”

November 2023

• Confidentiality Coalition comments in advance of the House E&C Subcommittee on Health hearing on, “Understanding How AI is Changing Health Care.”
• HLC letter to the Senate Finance Committee regarding their hearing, “Ensuring Medicare Beneficiary Access: A Path to Telehealth Permanency”
• HLC response to the Department of Health and Human Services current Healthy People 2030 objectives.
• HLC joint letter urging congressional leadership to reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA)
• HLC joint letters to House E&C and W&M committees and Senate Finance Committee in support of S. 2407/H.R. 4818, the “Treat and Reduce Obesity Act” (TROA)

October 2023

• HLC letter to the Senate Special Committee on Aging in advance of their hearing, “Unlocking Hope: Access to Therapies for People with Rare, Progressive, and Serious Diseases”
• HLC response to Senator Cassidy’s RFI on mechanisms to modernize the Centers for Disease Control and Prevention (CDC)
• HLC Joint letter urging CMS to protect provider privacy by ensuring telehealth providers are not required to provide home or other personal addresses in Medicare enrollment or billing forms
• HLC letter to sponsors in support of the “Healthcare Workforce Resilience Act”
• HLC response to the House Budget Committee’s Health Care Task Force RFI on solutions to modernize the nation’s healthcare system to both improve patient outcomes and reduce spending.
• HLC response to HHS, DOL, and Treasury Mental Health Parity and Addiction Equity Act (MHPAEA) proposed rule
• HLC response to House Committee on Ways and Means RFI on solutions to reshape the nation’s healthcare system and bring new access to care in rural and underserved areas.
• HLC joint letter to Congress urging support for H.R. 4752/S. 2379, the “Concentrating on High-Value Alzheimer’s Needs to Get to an End Act”
• HLC joint letter to the Domestic Policy Council proposing avenues for Medicaid MCOs to help complete reenrollment forms

September 2023

• HLC letter to the Senate Finance Committee hearing, “Aging in Place: The Vital Role of Home Health in Access to Care”
• HLC letter to House W&M supporting H.R. 5688, the “Bipartisan HSA Improvement Act,” and H.R. 5687, the “HSA Modernization Act,” in advance of an HSA markup
• HLC joint letter in response to the CY24 OPPS/ASC proposed rule urging CMS to implement the NOPAIN Act sooner than 2025
• HLC joint letter to CMS asking it not to finalize the price stacking provision in its Medicaid Drug Rebate Program proposed rule.
• HLC joint letter to the National Association of Medicaid Directors and the National Association of Insurance Commissioners encouraging automatic enrollment programs
• HLC joint letter urging CMS to extend home address flexibility to protect the privacy and safety of healthcare providers.
• HLC comments in advance of House E&C hearing, “Examining Policies to Improve Seniors’ Access to Innovative Drugs, Medical Devices, and Technology.”
• HLC comments on CMS’ Medicare Prescription Payment Plan draft part one guidance
• HLC joint letter urging HHS to remove barriers to access for critical COVID-19 antiviral treatments, particularly for historically underserved populations.
• HLC joint letter endorsing the John Lewis Equality in Medicare and Medicaid Treatment Act
• HLC joint letter to CMS supporting the inclusion of caregiver training services in the proposed CY24 Medicare Physician Fee Schedule
• Group letter to sponsors in support of S. 1355, the “Electronic Prescribing for Controlled Substances Act”

August 2023

• HLC response to CMS transitional coverage for emerging technologies (TCET) proposed pathway

July 2023

• Group letter to sponsors in support of the “Value in Health Care Act of 2023”
• Group letter to House Appropriations Committee opposing cuts to the U.S. Preventive Services Task Force (USPSTF)
• Group letter to Senate Appropriations Committee opposing cuts to the U.S. Preventive Services Task Force (USPSTF)
• HLC response to CMS Medicaid Drug Rebate Program proposed rule
• HLC joint letter in support of H.R. 3799, the CHOICE Arrangement Act in advance of the House floor vote
• HLC joint response to CMS Ensuring Access to Medicaid Services Proposed Rule
• HLC comments in advance of Senate HELP Committee hearing, “Superbugs: The Impact of Antimicrobial Resistance on Modern Medicine.”
• HLC comments on the Senate HELP PAHPA Reauthorization Discussion Draft.
• HLC response to House E&C Committee and Senate Finance Committee RFI on drug shortages
• HLC feedback on Senator Cassidy’s dual eligible discussion draft legislation
• HLC response to CMS Medicaid Managed Care Access, Finance, and Quality Proposed Rule

June 2023

• HLC letter in advance of Senate Special Committee on Aging hearing, “Before Disaster Strikes: Planning for Older Americans and People with Disabilities in All Phases of Emergencies.”
• HLC support letter to Rep. Gallego for co-sponsoring H.R. 2389, the “Resident Physician Shortage Reduction Act”
• HLC support letter to the House sponsors for H.R. 2389, the “Resident Physician Shortage Reduction Act”
• HLC support letter to the Senate sponsors for S. 1302, the “Resident Physician Shortage Reduction Act”
• HLC letter supporting the Sequoia Project as TEFCA’s Recognized Coordinating Entity.
• HLC letter in advance of House Education and the Workforce hearing, “Competition and Transparency: The Pathway Forward for A Stronger Health Care Market.”
• HLC joint letter urging Congress to include H.R. 3577, the “Medical and Health Stockpile Accountability Act” as part of the “Pandemic and All-Hazards Preparedness Act” (PAHPA) reauthorization
• HLC joint letter to House W&M and Education & Workforce committees in support of affordable health coverage for employees of small businesses
• HLC joint letter to House W&M Committee in support of H.R. 1843/S. 1001, the “Telehealth Expansion Act of 2023”
• HLC Comments in advance of House E&C hearing, “Examining Proposals that Provide Access to Care for Patients and Support Research for Rare Diseases.”
• HLC joint letter supporting H.R. 2377/S. 1000, the “Saving Access to Laboratory Services Act”
• HLC response to CMS FY24 Inpatient Prospective Payment Systems Proposed Rule

May 2023

• HLC joint letter urging Congressional leaders to stop the IRA Cuts to Part B Medicare
• HLC letter to the FDA in advance of its lecanemab advisory committee meeting
• HLC letter of Support for the Stockpile Accountability Act
• HLC joint letter thanking President Biden for including support for family caregivers in his Executive Order issued on April 18.
• HLC joint letter to Senate sponsors in support of S. 1302, the “Resident Physician Shortage Reduction Act”
• HLC joint letter urging CMS to establish an operational model for the retrospective approach to effectuate the Inflation Reduction Act’s Maximum Fair Price.
• HLC joint letter urging House and Senate appropriators to fully fund the Office of the National Coordinator for Health Information Technology at the President’s proposed FY24 budget request.
• HLC comments in advance of House W&M hearing, “Health Care Price Transparency: A Patient’s Right to Know.”
• HLC comments in advance of the House E&C hearing, “Preparing for and Responding to Future Public Health Security Threats.”
• HLC joint letter to Representatives Terri Sewell and Brian Fitzpatrick in support of H.R. 2389, the “Resident Physician Shortage Reduction Act”
• HLC letter expressing concerns over proposals to limit intellectual property protections for COVID-19 diagnostic tools and therapeutics under the World Trade Organization’s TRIPS agreement.

April 2023

• HLC joint letter supporting the Chronic Care Management Improvement Act of 2023.
• HLC joint letter to the House and Senate Appropriators requesting the removal of Section 510 in the FY 24 Budget.
• HLC comments in advance of the House E&C hearing, “Examining Existing Federal Programs to Build a Stronger Health Workforce and Improve Primary Care.” 
• HLC joint letter thanking President Biden for including an increase in funding for the Agency for Healthcare Research and Quality in its staffing and administrative support for the U.S. Preventive Services Task Force in the Fiscal Year 2024 budget proposal.
• HLC joint letter urging appropriators to increase funding for the CDC’s Social Determinants of Health program, within the National Center for Chronic Disease Prevention and Health Promotion in line with President Biden’s FY2024 request.
• HLC response to CMS’ Medicare Drug Price Negotiation Program Guidance
• HLC response to the Office of Management and Budget’s initial proposal on race and ethnicity statistical standards

March 2023

• HLC joint letter urging Congress to support and enact H.R. 1770, the “Equitable Community Access to Pharmacist Services Act”
• HLC and Duke-Margolis joint response to Senate PAHPA RFI
• HLC letter in advance of the House E&C hearing, “Lowering Unaffordable Costs: Examining Transparency and Competition in Health Care.”
• HLC joint letter urging Congress to provide permanent protections for the DACA program and Dreamers.
• HLC response to the Senate HELP Committee’s RFI on the drivers of healthcare workforce shortages
• HLC letter to the Senate Special Committee on Aging hearing on “Uplifting Families, Workers, and Older Adults: Supporting Communities of Care.”
• HLC Statement Opposing Expansion of TRIPS Agreement Flexibilities.
• HLC and Duke-Margolis Center for Health Policy Comments for PAHPA RFI.
• HLC letter to CMS on their initial guidance for the Medicare Part B and Part D Prescription Drug Inflation Rebate Program.
• HLC letter to CMS on advancing interoperability.
• HLC joint letter urging the Senate HELP Committee to include the PASTEUR Act in any moving legislative vehicle this year, including the reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). 
• HLC joint letter urging Representatives Hudson and Eshoo to include the PASTEUR Act in any moving legislative vehicle this year, including the reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). 
• HLC joint letter urging the House Ways and Means Committee to include the PASTEUR Act in any moving legislative vehicle this year, including the reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). 
• HLC joint letter urging the House Energy and Commerce Committee to include the PASTEUR Act in any moving legislative vehicle this year, including the reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). 
• Confidentiality Coalition letter to the National Telecommunications and Information Administration on privacy, equity and civil rights.
• HLC joint letter urging CMS to reconsider implementation of the risk adjustment changes in the 2024 Advance Notice.
• HLC letter to Senate HELP Committee in advance of its hearing on “Community Health Centers: Saving Lives, Saving Money.”
• HLC response to the Centers of Medicare and Medicaid Services 2024 Medicare Advance and Part D Advance Notice.

February 2023

• Confidentiality Coalition comments in advance of the House E&C Subcommittee on Consumer Protection & Commerce hearing on, “Promoting U.S. Innovation and Individual Liberty through a National Standard for Data Privacy.”
• Confidentiality Coalition response to the Federal Communications Commission on their proposal to update data breach reporting requirements.
• HLC letter to Senate HELP Committee in advance of its hearing on, “Examining Health Care Workforce Shortages: Where Do We Go From Here?”
• HLC response to CMS 2024 Medicare Advantage and Part D Proposed Rule

January 2023

• Group letter to HHS on 42 CFR Part 2 proposed rule
• HLC response to CMS’s 2024 Notice of Benefit and Payment Parameters proposed rule
• HLC letter to Sen. Brian Schatz (D-HI) and Rep. Mike Thompson (D-CA) on CONNECT for Health Act
• Group Letter to Centers for Medicare and Medicaid Services (CMS) in support of Medicare Advantage
• HLC letter to White House Office of Science and Technology Policy (OSTP) on Clinical Research Infrastructure and Emergency Clinical Trials Request for Information
• HLC letter to White House Office of Science and Technology Policy (OSTP) on Data Collection for Emergency Clinical Trials and Interoperability Pilot
• HLC response to Senator Cassidy’s RFI on dual eligibles

December 2022

• Group letter in support of H.R. 9310, the Preventive Services Early Act
• HLC letter in support of S. 3904, the Healthcare Cybersecurity Act
• Confidentiality Coalition letter to Sen. Mark Warner (D-VA) on cybersecurity in healthcare white paper

November 2022

• Group Letter to Congress in support of H.R. 1384/S. 445, the Mainstreaming Addiction Treatment Act.
• Group letter urging Congress to enact H.R. 3932/S. 2076, the PASTEUR Act in the end of year package to address the growing crisis of antimicrobial resistance.
• HLC letter to the Department of Health and Human Services (HHS) on implementation of the Inflation Reduction Act (IRA)
• Group letter to Congress supporting extension of telehealth services for high-deductible health plans (HDHPs)
• Group letter to Drug Enforcement Agency (DEA) on Special Registration for controlled substances via telehealth
• Confidentiality Coalition letter to Federal Insurance Office (FIO) on coverage for catastrophic cyber incidents
• Confidentiality Coalition letter to Cybersecurity and Infrastructure Security Agency (CISA) on breach reporting request for information
• HLC joint letter supporting proposed changes to the ICD-10 Coordination and Maintenance codes.
• Group letter to Congress supporting extension of telehealth flexibilities
• Group letter to Office of Management and Budget (OMB) supporting additional funding to U.S. Preventive Services Task Force (USPSTF).

October 2022

• Confidentiality Coalition to Federal Trade Commission on commercial surveillance advanced notice of proposed rulemaking
• HLC responds to the Centers for Medicare and Medicaid Services (CMS) Make Your Voice Heard RFI to promote efficiency, reduce burden, and advance equity within CMS programs.
• HLC comments in response to the NPRM entitled, “Streamlining the Medicaid, Children’s Health Insurance Program, and Basic Health Program Application, Eligibility Determination, Enrollment, and Renewal Processes.”
• HLC letter to House of Representatives on proposed improvements to MACRA
• Group letter to HHS in support of PASTEUR Act

September 2022

• Joint letter urging Congressional support for the Saving Access to Laboratory Services Act
• Group letter to Senate supporting extension of COVID-19 telehealth waivers.
• HLC letter to Senate Committee on Judiciary in advance of its hearing, “Flatlining Care: Why Immigrants Are Crucial to Bolstering Our Health Care Workforce.”
• HLC letter to CMS on CY23 Physician Fee Schedule Proposed Rule

August 2022

• HLC response to CMS’s Medicare Advantage RFI
• Group letter to Senate leadership in support of the Mainstreaming Addiction Treatment Act (H.R. 1384 / S. 445).
• Group Letter to HHS Requesting Additional Guidance on Information Blocking Regulations
• HLC response to the Office of the Assistant Secretary for Health’s RFI on Primary Healthcare

July 2022

• HLC letter to House in support of H.R. 4040, the “Advancing Telehealth Beyond COVID-19 Act”
• HLC support letter for H.R. 6087, “Improving Access to Workers Compensation for Injured Federal Workers Act”

June 2022

• Group letter in support of H.R. 7353, the Telehealth Benefit Expansion for Workers Act of 2022
• Group letter to CMS in support of the Medicare Advantage program
• HLC letter in advance of E&C hearing on, “Protecting America’s Seniors: Oversight of Private Sector Medicare Advantage Plans.”
• HLC letter to Centers for Medicare and Medicaid Services (CMS) on FY23 inpatient prospective payment systems (IPPS) proposed rule
• HLC comments on draft FDA clinical trial guidance
• Confidentiality Coalition letter to House Energy and Commerce Committee on federal privacy legislation hearing
• Confidentiality Coalition letter to HHS Office of Civil Rights on HIPAA Civil Monetary Penalties and Recognized Security Practices RFI
• HLC joint letter encouraging House Energy and Commerce Committee to advance SDOH legislation
• HLC response the IRS proposed rule on “Affordability of Employer Coverage for Family Members of Employees.”
• Group letter requesting funding for the CDC’s National Center for Chronic Disease Prevention and Health Promotion Social Determinants of Health program.

May 2022

• Group letter to National Artificial Intelligence Advisory Committee supporting creation of healthcare subcommittee
• HLC letter to Department of Labor (DOL), Internal Revenue Service (IRS) and Centers for Medicare and Medicaid Services (CMS) requesting additional guidance on mental health parity compliance
• HLC joint FY 2023 appropriations letter urging House and Senate leaders to continue the momentum toward the National Alzheimer’s Plan goals.
• Group letter expressing support for section 809 of the Food and Drug Amendments of 2022 (H.R. 7667) on pre-approval information exchange (PIE).
• Group letter urging the E&C Committee to add the “Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act,” (H.R. 3932/S.2076) to PDUFA reauthorization legislation.
• Mainstreaming Addiction Treatment Act (MAT Act, H.R. 1384/S. 445),” as a provision of the “Restoring Hope for Mental Health and Well-Being Act
• Confidentiality Coalition letter to Senate HELP Committee on cybersecurity hearing
• HLC letter to Federal Communications Commission (FCC) on request relating to enrollment in Medicaid
• Confidentiality Coalition letter to Securities and Exchange Commission (SEC) on cybersecurity incident disclosure proposed rule
• Group letter to House Appropriations Committee on patient matching in FY23 appropriations
• Group letter to Senate Appropriations Committee on patient matching in FY23 appropriations

April 2022

• HLC joint letter urging Congress to replenish HRSA’s COVID-19 Uninsured Relief Fund
• Group to House/Senate Appropriations Committees supporting FY23 funding for CDC Data Modernization Initiative
• Confidentiality Coalition to National Institute of Standards and Technology (NIST) on improvements to NIST Cybersecurity Framework.
• HLC letter to CMMI on Strengthening Equitable Access to Advanced Primary Care Roundtable
• Group Letter in Support of Section 410 of the Cures 2.0 Act, Generally Accepted Standard for Electronic Prescribing.
• HLC letter in response to the Senate Committee on Finance hearing, “Behavioral Health Care When Americans Need It: Ensuring Parity and Care Integration.”
• HLC letter to House Energy and Commerce Committee on mental health hearing

March 2022

• Group letter in support of equitable community access to pharmacist services
• HLC letter to White House Office of Science and Technology Policy on community health RFI
• HLC comments in advance of Senate Finance Committee hearing, “Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare
• HLC letter to Senate Aging Committee on at-home care hearing
• HLC letter to Federal Communications Commission (FCC) on Affordable Connectivity Program (ACP) enrollment
• Confidentiality Coalition letter to Federal Trade Commission (FTC) and the Department of Justice (DOJ) on request for information on merger enforcement guidelines
• Group letter in support of Hospital Inpatient Services Modernization Act
• HLC letter in support of Hospital Inpatient Services Modernization Act
• HLC response to CMS 2023 Medicare Advantage and Part D Proposed Rule
• HLC response to CMS 2023 Medicare Advantage and Part D Advance Notice
• HLC letter to House Ways and Means Committee in advance of its hearing, “America’s Mental Health Crisis.
• HLC additional comments to Senate HELP Committee on PREPARE Pandemics Act
• HLC letter to HHS Assistant Secretary for Preparedness and Response on 2023-2026 National Health Security Strategy

February 2022

• Group letter to Congress on extending Medicare sequester moratorium
• HLC letter to House Committee on Judiciary in advance of its hearing, “Is There a Doctor in the House? The Role of Immigrant Physicians in the U.S. Healthcare System.”
• HLC letter of support for CMMI’s Global and Professional Direct Contracting model.
• Recruiting, Revitalizing & Diversifying: Examining the Health Care Workforce Shortage
• HLC letter to Senate Appropriations Committee on broadband programs hearing
• HLC joint letter urging Senate HELP Committee to include the LINC to Address Social Needs Act in the final version of the PREVENT Pandemics Act
• HLC letter to Senate HELP Committee on PREVENT Pandemics Act
• Group letter to National Telecommunications and Information Administration on implementation of the Infrastructure Investment and Jobs Act
• HLC joint letter to House of Representatives in support of including the PASTEUR Act in the Cures 2.0 legislation.
• HLC letter to National Telecommunications and Information Administration on implementation of the Infrastructure Investment and Jobs Act
• HLC letter in advance of House Ways and Means hearing, “Bridging Health Equity Gaps for People with Disabilities and Chronic Conditions.”

January 2022

• Group letter to Congress on pathway to telehealth reform
• HLC response to HHS 2023 Notice of Benefit and Payment Parameters proposed rule
• Group letter to Congress supporting extension of Acute Hospital Care at Home (AHCAH) waiver
• Group letter to Congress on reinstating safe harbor for high-deductible health plans to offer telehealth services
• HLC letter to Senate HELP Committee on federal officials variants hearing

December 2021

• HLC letter to Federal Communications Commission (FCC) on implementation of Affordable Connectivity Program (ACP)
• HLC comments in advance of the CMMI health equity strategy roundtable
• NDHI Disaster Preparedness and Response Group Letter to Secretary Becerra.

November 2021

• Group letter in support of H.R. 2554, the “Opioid Prescription Verification Act.”
• HLC letter to HHS on FY22-FY26 Strategic Plan
• Group letter to Congress on including telehealth as an excepted benefit for ERISA plans
• HLC letter opposing Medicaid DSH cuts in H.R. 5376, the “Build Back Better (BBB) Act.”
• HLC letter to Senate Finance Committee on request for information to address unmet mental health needs

October 2021

• Group letter to governors on expiration of emergency telehealth/licensure flexibilities
• Group letter to Senate Judiciary Committee on S. 2428, the False Claims Amendments Act
• HLC letter to House Homeland Security on ensuring equity in disaster preparedness hearing
• Group letter to Congress on permanently extending telehealth safe harbor for HDHPs
• HLC letter in support of S. 3039, the “Social Determinants Accelerator Act.”
• HLC letter to House Energy and Commerce committee in advance of its hearing, “Caring for America: Legislation to Support Patients, Caregivers, and Providers.”
• Increasing Military Families’ Access to Counseling Services is the goal of bipartisan COMFORT Act (S. 3021)
• HLC letter to National Biodefense Science Board on September 28 public meeting
• HLC letter to Senate Finance Committee hearing on “Health Insurance Coverage in America: Current and Future Role of Federal Programs.”
• HLC letter to Senate Judiciary Committee on S. 2428, the False Claims Amendment Act
• HLC letter to House Energy & Commerce Committee on supply chain hearing
• HLC letter to Senate Commerce Committee on telehealth hearing
• HLC letter in support of H.R. 5541, the Primary and Virtual Care Affordability Act
• Confidentiality Coalition letter to the Senate Commerce Committee on enhancing data security hearing

September 2021

• Friends of NQF letter to the Hill requesting quality improvement and measurement funding.
• Group letter to House Leadership supporting the family caregiver tax credit.
• Thank you letter to Chairman Neal for including a family caregiver tax credit consistent with the “Credit for Caring Act” legislation.
• Thank you letter to Rep. Sanchez for including a family caregiver tax credit consistent with the “Credit for Caring Act” legislation.
• Confidentiality Coalition letter to Senate Commerce Committee on consumer privacy hearing
• Healthcare Groups Band Together to Call for Congress, Administration to Support Pandemic Preparedness Partners
• HLC response to Congressional Social Determinants of Health RFI
• HLC letter to CMMI on recommendations at 10 years
• HLC letter to CMS on CY22 Outpatient Prospective Payment Systems (OPPS) proposed rule
• HLC joint letter to the U.S. House of Representatives encouraging co-sponsorship of H.R. 3354, the Concentrating on High-Value Alzheimer’s Needs to Get to an End Act
• HLC joint letter to the U.S. Senate encouraging co-sponsorship of H.R. 3354, the Concentrating on High-Value Alzheimer’s Needs to Get to an End Act
• Group letter encouraging CMS to create a permanent audio-only modifier in CY22 Physician Fee Schedule proposed rule
• Group letters to the House and Senate calling for action to address the growing number of Americans living with obesity who lack access to comprehensive care.
• Group letter urging the Administration to address health equity by providing access to comprehensive care for chronic disease.
• EPCS Coalition Comment Letter to CMS on CY 2022 Physician Fee Schedule Rule
• HLC support letter for H.R. 2503, the Social Determinants Accelerator Act
• HLC joint letter urging House Energy and Commerce committee to oppose H.R. 3 in the upcoming reconciliation package
• HLC letter to ONC on Draft Developer-Reported Measures for the Electronic Health Record Reporting Program.
• HLC joint letter to Congress on the expansion of supplemental benefits
• HLC joint letter to CMS in response to the Medicare Physician Fee Schedule proposed rule
• HLC letter to CMS on CY 2022 Physician Fee Schedule proposed rule
• Group letter on CY22 Physician Fee Schedule proposed rule

August 2021

• HLC letter to PCORI on proposed National Priorities for Health
• HLC letter urging the United States Department of State to prioritize the processing of immigrant visas for eligible foreign-trained nurses.
• Group letter requesting guidance from CMS for operations planning upon the conclusion of the COVID-19 public health emergency.
• HLC letter of support for AIM-AHEAD initiative.
• HLC support letter for the legislative proposal to amend 10 U.S.C. 1781 to grant license reciprocity in any state to mental and behavioral healthcare providers contracted by the Department of Defense.

July 2021

• Group letter in support of the Seniors’ Chronic Care Management Improvement Act of 2021.
• HLC response to House E&C and Senate HELP Committees Public Option RFI
• HLC response to HHS Notice of Benefit and Payment Parameters for 2022 and Pharmacy Benefit Manager Standards
• Confidentiality Coalition letter to House Energy & Commerce Committee on consumer protection hearing
• Confidentiality Coalition letter to NCVHS on request for comments
• HLC letter to House E&C committee in advance of social determinants of health markup
• Group letter to Congressional leadership on Medicare telehealth reform
• Group letter opposing harmful policy changes to Medicare Part D.
• HLC letter to House Education & Labor Committee hearing , “Care for Our Communities: Investing in the Direct Care Workforce.”
• Partnership to Amend 42 CFR Part 2 recommendations to SAMHSA for the next Part 2 rule
• HLC letter on 21^st Century Cures 2.0 discussion draft
• HLC letter to Senate HELP Committee on federal officials hearing
• Group letter to DEA Administrator to support the complete removal of the X-Waiver restrictions on prescribing buprenorphine.
• Group letter in support of the Medical Nutrition Therapy Act of 2021 (S. 1536)
• Group letter in support of the Medical Nutrition Therapy Act of 2021 (H.R. 3108)
• HLC response to OMB’s “Methods and Leading Practices for Advancing Equity and Support for Underserved Communities Through Government” RFI.
• HLC letter of support for H.R. 4131/S.2210, the “Better Care Better Jobs Act.”
• HLC letter urging Congress to  close the Medicaid coverage gap in the American Families Plan.
• HLC letter to Senate HELP Committee on disaster preparedness RFI
• HLC letter in support of S. 2061, the Telemental Health Care Access Act
• HLC letter in support of H.R. 4058, the Telemental Health Care Access Act

June 2021

• Group letter calling for cosponsors for the bipartisan Credit for Caring Act (H.R. 3321).  Washington Post AD.
• HLC letter to House Energy & Commerce committee hearing on “Empowered by Data: Legislation to Advance Equity and Public Health.”
• HLC letter to CMS on FY22 Inpatient Prospective Payment System (IPPS) proposed rule
• Group letter urging Leadership to include the Public Health Infrastructure Saves Lives Act (PHISLA, S. 674) in the infrastructure and jobs legislation.
• HLC joins other members of the Enrollment Coalition in supporting systems to integrate safety-net programs and increase health coverage enrollment.
• Group letter on the PREVENT Diabetes Act Senate Introduction
• HLC letter to U.S. Senate Special Committee on Aging in advance of their hearing, “21st Century Caregiving: Supporting Workers, Family Caregivers, Seniors and People with Disabilities.
• HLC letter to Rep. Nunes on TRIPS waiver legislation
• HLC letter to Senate Finance Committee on mental health hearing
• HLC letter to Senate HELP Committee for vaccine hearing
• HLC additional comments to CMS on value-based arrangements within Medicaid
• HLC letter to House Energy and Commerce Committee on vaccine hearing
• Group letter to HHS and CMS supporting Medicare Advantage audio-only telehealth encounters to be included in risk adjustment calculations

May 2021

• HLC FY 2022 appropriations letter to U.S. Senate in support of Alzheimer’s funding
• HLC FY 2022 appropriations letter to U.S. House in support of Alzheimer’s funding
• HLC letter to House Labor HHS Appropriations committee in support of NIH funding.
• HLC letter to Senate HELP committee in advance of maternal health markup.
• HLC letter to Senate Labor HHS Appropriations committee in support of NIH funding.
• Group letter in support of the “Pharmacy and Medically Underserved Areas Enhancement Act” (H.R. 2759/S.1362).
• Credit for Caring (H.R. 3321/S. 1670) Group Support Letter
• HLC letter in support of Telehealth Expansion Act
• HLC letter to House Appropriations Committee on FY22 CDC budget request hearing
• HLC letter to Senate HELP committee in advance of its hearing “A Dire Shortage and Getting Worse: Solving the Crisis in the Health Care Workforce.”
• HLC letter to Senate Appropriations Committee on FY22 CDC budget request hearing
• HLC letter to Senate Homeland Security and Governmental Affairs on medical supply chain hearing
• HLC letter to Senate Finance Committee on health care flexibilities hearing
• HLC letter to House Appropriations Committee on universal broadband hearing
• HLC letter to Senate Finance Committee on mental health/addiction services hearing
• Confidentiality Coalition letter to HHS Office of Civil Rights on HIPAA Coordinated Care Proposed Rule
• HLC letter to House Education and Labor committee hearing on “Lower Drug Costs Now: Expanding Access to Affordable Health Care.”
• HLC letter to House Energy & Commerce Committee on broadband equity hearing
• Confidentiality Coalition letter to House Homeland Security Committee on ransomware hearing
• HLC letter to House Energy & Commerce committee hearing on “Negotiating a Better Deal: Legislation to Lower the Cost of Prescription Drugs.”

April 2021

• HLC letter to AHRQ for RFI on racial bias in clinical algorithms
• HLC letter to House Ways & Means Committee on telehealth hearing
• Group letter supporting increased investment in CDC Data Modernization Initiative for FY22
• HLC letter to Senate HELP Committee on substance use hearing
• HLC letter to congressional leadership on infrastructure package
• Group letter urging House and Senate leaders to keep any international reference pricing proposals out of drug pricing reform legislation.
• HLC letter to Senate HELP committee hearing on “COVID-19 Recovery: Supporting Workers and Modernizing the Workforce Through Quality Education, Training, and Employment Opportunities.”
• HLC letter to House Agriculture Committee on expanding rural broadband capabilities hearing
• HLC letter to CMS on MCIT comment period extension
• HLC joint letter to HHS Secretary Becerra outlining several diabetes priorities.
• Group letter supporting Ensuring Parity in MA for Audio-Only Telehealth Act.
• Group letter aimed at strengthening funding and support for the implementation of the 2020-2025 Dietary Guidelines for Americans.
• Group letter urging HHS to remove regulatory barriers to Medication Assisted Treatment
• HLC letter to House Energy & Commerce Committee on substance use hearing
• HLC letter to Senate Appropriations Homeland Security Subcommittee on FEMA’s COVID-19 response.
• Group letter supporting FY 2022 funding for the CDC’s Social Determinants of Health program.
• EPCS Coalition letter on prioritizing report language urging CMS to promptly undertake the requisite rulemaking so that the agency is able to establish a January 1, 2022 deadline for EPCS compliance.
• HLC letter to Senate HELP subcommittee hearing on “Why Does the U.S. Pay the Highest Prices in the World for Prescription Drugs?”
• Patient identification group letter to the House Appropriations Committee requesting the repeal of Section 510 in the FY22 Labor-HHS appropriation bill.
• Patient identification group letter to the Senate Appropriations Committee requesting the repeal of Section 510 in the FY22 Labor-HHS appropriation bill.

March 2021

• HLC joint introduction letter to the Senate Committee on Finance.
• Letter to HELP committee hearing on “Examining Our COVID-19 Response: Improving Health Equity Outcomes by Addressing Health Disparities.”
• HLC letter to Senate HELP subcommittee hearing on “Why Does the U.S. Pay the Highest Prices in the World for Prescription Drugs?”
• Letter to Energy & Commerce hearing on “Building on the ACA: Legislation to Expand Health Coverage and Lower Costs.”
• HLC letter to Senate Committee on Aging in advance of it’s hearing on “COVID-19 One Year Later: Addressing Health Care Needs for At-Risk Americans.”
• HLC letter to Senate HELP Committee on COVID-19 Federal Officials Hearing
• HLC letter in support of Telehealth Modernization Act
• Group letter urging Congress to eliminate looming cuts by the Medicare sequester moratorium and PAYGO.
• HLC letter to Senate HELP Committee on COVID-19 Response Hearing
• Group letter to Biden Administration and Congress encouraging use of digital health tools
• Group letter in support of the Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act of 2021.
• HLC letter to House Energy & Commerce Committee on telehealth hearing.

February 2021

• HLC letter in support of S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act of 2021.
• HLC letter to House Ways & Means Committee on COVID-19 immunization hearing.
• HLC letter to House Appropriations Committee on public health infrastructure hearing.
• HLC joint letter urging House leadership to support the Older American Act provisions in the budget reconciliation package.
• HLC joint letter urging Senate leadership to support the Older American Act provisions in the budget reconciliation package.
• Group letter calling on Congress to strengthen America’s Medicaid program in upcoming COVID-19 relief legislation
• Group letter urging Congressional Leadership to support increased, sustained annual funding for public health infrastructure
• HLC support letter for H.R. 379, the “Improving Social Determinants of Health Act.”
• HLC support letter for S. 104, the “Improving Social Determinants of Health Act.”
• HLC joint letter urging Congress to support temporary COBRA continuation health coverage. 
• HLC letter to the 117^th Congress on COVID-19 key priorities
• HLC letter to House Energy & Commerce Committee on vaccine, testing and medical supply chain hearing
• HLC joint letter urging Congress to pass COVID-19 liability protections

January 2021

• HLC joint letter to the Biden-Harris transition team outlining coverage recommendations.
• HLC letter to Health Care Innovation Caucus on Stark/AKS and MDRP modernization
• Confidentiality Coalition letter to CMS on provider burden/prior authorization rule
• Group statement calling for a national Alzheimer’s and related dementias (ADRD) prevention goal.

December 2020

• HLC letter of support for H.R. 9035, the Permanency for Audio-Only Telehealth Act
• HLC joint letter urging Congress to delay the Most Favored Nation Model for Medicare Part B drugs.
• HLC letter to OASH RFI on using novel technologies for underserved populations
• Confidentiality Coalition letter to CMS requesting extension of Prior Authorization/Provider Burden proposed rule
• HLC letter to HHS on COVID-19 best practices
• Letter to CMS on Most Favored Nation (MFN) interim final rule
• The Electronic Prescribing of Controlled Substances (“EPCS”) Coalition Group Letter to Congressional Champions
• HLC letter to ONC on USCDI v2 Standards
• Confidentiality Coalition letter to FDA on communicating cybersecurity vulnerabilities
• HLC group letter urging Congress to include a COBRA subsidy in any end-of -year package.
• HLC comment letter to HHS on retrospective regulatory review proposed rule
• HLC joint letter urging Congress to strengthen the health care workforce

November 2020

• HLC joint letter urging Congress to extend the current moratorium on the Medicare sequestration cuts until the end of the COVID-19 public health emergency.
• Joint letter to President-Elect Biden urging a reprioritization of the Office of National Drug Control Policy
• HLC letter to U.S. Senate on COVID-19 Key Priorities
• HLC responds to CMS Part 2 of 2022 for Medicare Advantage Capitation Rates and Part C and Part D Payment Policies
• HLC comment letter to CMS on MCIT Proposed Rule
• HLC joint letter to Congress on increasing Medicaid funding
• HLC responds to CMS Part 1 of 2022 Medicare Advantage Capitation Rates and Part C and Part D Payment Policies. 

October 2020

• Confidentiality Coalition letter to FCC on TCPA exemptions
• HLC comment letter to CMS on EPCS RFI
• HLC comment letter to CMS on FY21 PFS Proposed Rule
• HLC joint letter to House Energy & Commerce Committee on TCPA healthcare exemptions
• HLC letter on Cures 2.0 legislation
• HLC joint letter encouraging the Drug Enforcement Agency to implement provisions to allow writing prescriptions of controlled substances via telehealth appointments without prior in-person exams.
• HLC joint letter to the National Governors Association on the impact on voters with rare, serious and chronic diseases as a result of COVID-19
• HLC responds to HHS Economic Mobility RFI
• HLC joint response to CMS Electronic Prescribing of Controlled Substance RFI

September 2020

• Confidentiality Coalition letter to eHealth Initiative on draft privacy framework for health data
• HLC letter to House Energy and Commerce Committee on the Affordable Care Act and the COVID-19 Pandemic
• HLC comment letter to CMS on FY21 ESRD PPS Proposed Rule
• HLC letter to ONC on improvements to patient matching and identification

August 2020

• HLC letter of support for S. 4456, the ‘Patient Matching Improvement Act.’
• HLC letter to FTC for data portability workshop
• Confidentiality Coalition to FTC for data portability workshop
• HLC letter to House Ways and Means Committee on rural telehealth challenges
• HLC letter to Ways and Means Republicans in support of telehealth legislation
• Group letter in support of H.R. 7663, the ‘Protecting Access to Post-COVID Telehealth Act’
• HLC letter of support for S. 3595, the “Ensuring Understanding of COVID-19 to Protect Public Health Act”
• HLC support letter for the “Temporary Reciprocity to Ensure Access to Treatment Act.”

July 2020

• HLC letter to House Energy & Commerce Committee on COVID-19 vaccines
• HLC Letter to Senate VA Committee on rural telehealth
• HLC letter to House Select Committee on the Coronavirus Crisis on disaster preparedness
• Group letter to Congress supporting S. 4317, the “SAFE TO WORK Act”.
• HLC letter to the Senate Special Committee on Aging addressing health disparities amid the COVID-19 pandemic.
• Group letter urging Congress to prioritize robust federal funding for the critical testing needed to reopen the country.
• HLC comment letter to CMS on FY21 IPPS Proposed Rule
• HLC comment letter to CMS on value-based arrangements within Medicaid
• HLC letter to OASH on an RFI related to health resilience
• Group letter encouraging future COVID-19 legislative packages to strengthen Medicaid
• Group letter to improve outcomes for patients with diabetes

June 2020

• HLC letter to the House Ways and Means Committee on the impact of COVID-19 on communities of color
• HLC letter to the Senate HELP Committee on telehealth lessons learned from the COVID-19 pandemic.
• HLC letter to the House Energy and Commerce Committee on confronting racial and ethnic disparities in COVID-19 and the health care system
• Group letters to Congress on eliminating telehealth barriers

May 2020

• HLC support letter for H.R. 6810, the “Health Care Protection Act.”
• Group letter to Congress supporting employer liability protections
• HLC letter to the Senate Commerce Committee on the state of broadband services amid the COVID-19 pandemic.
• Letter to the Senate Judiciary Committee supporting employer liability protections

April 2020

• HLC letter to the Departments of Homeland Security, Labor, and State on nonimmigrant visa measures to address the impact of the COVID-19 pandemic on the U.S. medical workforce.
• Confidentiality Coalition letter to the FDA on modernizing the administrations data strategy.
• HLC support letter for H.R. 5924, “A bill to amend the Public Health Service Act to authorize a loan repayment program to encourage specialty medicine physicians to serve in rural communities experiencing a shortage of specialty medicine physicians, and for other purposes.” 
• Group letter to Congress on stabilizing Medicare Advantage provider practices affected by COVID-19
• HLC letter to U.S. Senate & House leadership on key policy issues for consideration in 4th COVID-19 legislation.
• HLC request to CMS and ONC on extending the time period for implementation of the interoperability rules.
• HLC responds to CMS Maternal and Infant Health Care in Rural Communities RFI
• HLC comments on CMS CY 2021 and 2022 Policy and Technical changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicaid Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly.

March 2020

• Group letter to Congress on COBRA subsidies during COVID-19 pandemic
• HLC Letter to CMS on access to Chimeric Antigen Receptor (CAR) T-cell therapies.
• Group letter to Senate leadership expressing support for S. 3539 to exempt telehealth services from certain high deductible health plan rules
• Group letter to the Federal Communications Commission requesting immediate action to adapt the Lifeline program to meet the COVID-19 crisis.
• Group letter in support of funding the White House Office of National Drug Control Policy
• Joint Association COVID-19 letter
• HLC Comments on ONC’s 2020-2025 Draft Federal Health IT Strategic Plan
• Group letter on strengthening telehealth for COVID-19
• Group letter to  Senate Appropriations in support of HL7 FHIR® standards-related activities for interoperability
• HLC statement to the U.S. Senate Committee on Homeland Security & Governmental Affairs hearing on “The Federal Interagency Response to the Coronavirus and Preparing for Future Global Pandemics.”
• HLC statement to the U.S. House of Representatives Committee on Science, Space, & Technology hearing on “Coronaviruses: Understanding the Spread of Infectious Diseases and Mobilizing Innovative Solutions.”
• HLC statement to the U.S. House of Representatives Subcommittee on National Security and Subcommittee on Economic and Consumer Policy hearing on “U.S. Biodefense and Response to the Novel Coronavirus Outbreak.”
• HLC statement to the U.S. House of Representatives Committee on Homeland Security hearing on “Confronting the Coronavirus: The Federal Response.”
• HLC responds to HHS Notice of Beneficiary Payment and Parameters proposed rule.
• HLC comments to CMS Medicare Advantage Advance Notice.
• Group Letter in Support H.R. 5741
• Joint Stakeholder Medicare Plan Finder Letter.
• HLC statement to the U.S. Senate Committee on Health, Education, Labor & Pensions hearing on “An Emerging Disease Threat: How the U.S. Is Responding to COVID-19, the Novel Coronavirus.”
• Group letter in support of re-introduction of the “Protecting Jessica Grubb’s Legacy Act.”
• HLC statement to the House Committee on Energy and Commerce Subcommittee on Health for their hearing “Combatting an Epidemic:  Legislation to Help Patients with Substance Use Disorders.”
• HLC Comments on the FDA’s “Importation of Prescription Drugs” proposed rule.

February 2020

• Group letter to U.S. Senate in support of the Older Americans Act
• HLC Supports H.R. 5741, the “Strengthening Innovation in Medicare and Medicaid Act”
• HLC response to CMS NPRM on Medicaid Fiscal Accountability Regulation
• HLC letter to the National Clinical Care Commission on policies, effectiveness, and limitations related to prevention and treatment of diabetes.
• HLC letter to Senate Special Committee on Aging hearing on “Home Health Care in Rural America”
• HLC statement to the House Committee on Ways & Means Subcommittee on Health hearing “More Cures for More Patients: Overcoming Pharmaceutical Barriers.”
• HLC written testimony to House Committee on Veterans’ Affairs Subcommittee on Technology Modernization hearing “Data Privacy and Portability at VA: Protecting Veterans’ Personal Data.”

January 2020

• HLC comments on House Energy and Commerce committee’s draft privacy legislation
• HLC Comments on the Transparency in Coverage Proposed Rule
• HLC support letter to House Energy Commerce Committee on legislation to Improve Americans’ Healthcare Coverage and Outcomes
• HLC letter to CMS on Scope of Practice Recommendations

---

 December 2019

• HLC Letter to EC on Universal Healthcare Coverage (002)
• HLC comments in response to the CMS Physician Self-Referral (Stark Law) Proposed Rule
• HLC Comments in response to the OIG Anti-Kickback Statute and Civil Monetary Penalty Proposed Rule
• HLC applauds the Senate Judiciary Committee for holding the hearing titled “Tackling the Opioid Crisis:  A Whole-of-Government Approach.”
• HLC responds to HHS PreventionX RFI
• HLC Comments on Cures 2.0 Request for Information
• Group letter encouraging the Administration to share its views with Congress on the impact of lifting the Patient ID ban
• Group letter to U.S. Senate in support of S. 2892, the Opioid Workforce Act
• Confidentiality Coalition letter to the U.S. Senate Committee on Commerce, Science, and Transportation on “Examining Legislative Proposals to Protect Consumer Data Privacy.”

November 2019

• Letter to House Ways and Means Committee in response to their Rural and Underserved Communities Health Task Force RFI
• Letter in response to CMS RFI on Program Integrity
• Letter to the House Small Business Committee hearing on “Upskilling the Medical Workforce: Opportunities in Health Innovationn
• Group letter to Senate Finance Committee urging long-term reauthorization of PCORI
• Group letter to the leadership of the House Energy & Commerce and Ways & Means Committees urging long-term reauthorization of PCORI

October 2019

• Group letter urging Congress to support delay of the Health Insurance Tax (HIT).
• Letter to the Senate Committee on Finance for the “Treating Substance Misuse in America:  Scams, Shortfalls, and Solutions” hearing.
• HLC comments on several bills being considered by the Health, Education, Labor, Pensions Committee
• HLC comments on the Health Resources and Services Administration’s RFI on Rural Access to Health Care Services
• HLC comments on SAMHSA’s  Confidentiality of Substance Use Disorder Patient Records Proposed Rule
• HLC’s comments on Development of a CMS Action Plan to Prevent Opioid Addiction and Enhance Access to Medication-Assisted Treatment

September 2019

• HLC Comments on the CY 2020 Hospital OPPS Proposed Rule
• CY 2020 Hospital Outpatient PPS Group Letter
• Medical Device Tax Repeal Group Letter
• Letter to the House Education and Labor Subcommittee on Health, Education, Labor, and Pension’s hearing “Making Health Care More Affordable: Lowering Drug Prices and Increasing Transparency.”
• HLC Letter on CMS’s Proposed Rule, “Medicare Program; Specialty Care Models to Improve Quality of Care and Reduce Expenditures.”
• HLC letter to Bipartisan Policy Center on recommendations to improve rural health

August 2019

• HLC comments in response to ASPE’s RFI: Ensuring Patient Access and Effective Drug Enforcement
• HLC comments in response to FCC notice of proposed rule on “Promoting Telehealth for Low-Income Consumers”
• HLC Letter in support of the “Telehealth Innovation and Improvement Act” (H.R.4013)
• HLC Letter in support of the “Telehealth Innovation and Improvement Act” (S.773)
• Letter in response to CMS RFI on “Reducing Administrative Burden to put Patients over Paperwork”
• HLC comments in response to CMS notice of proposed rule on “Nondiscrimination in Health and Health Education Programs or Activities”

July 2019

• Letter to U.S. House of Representatives in Support of H.R. 3796, the “Health Savings for Seniors Act”

June 2019

• Group letter to Congressional Leaders in support of the utilization of Real Time Benefit Tools
• Group letter to House Ways and Means in support of H.R. 3414, the “Opioid Workforce Act of 2019”
• Letter to Ways and Means in support of the full committee health legislation markup
• Group Letter in Support of H.R. 3436 which removes cost-sharing responsibilities for chronic care management services under the Medicare program
• Group letter in support of the Treat and Reduce Obesity Act (S.595/H.R.1530)
• Letter to the House Oversight and Government Reform Committee’s hearing “Medical Experts: Inadequate Federal Approach to Opioid Treatment and the Need to Expand Care.”
• HLC Comments on CMS’s NPRM FY 2020 Inpatient Prospective Payment System
• The Confidentiality Coalition submits commits on ONC’s Trusted Exchange Framework and Common Agreement (TEFCA) Draft 2
• Group letter to the U.S. House of Representatives in support of an amendment to the Labor-HHS appropriations bill to allow for a full range of patient matching solutions
• W&M letter on Pathways to Universal Health Coverage
• Group letter to Congressional Leaders on Binding Arbitration
• Letter to House Energy and Commerce Committee and Ways and Means Committee on draft proposal to modernize Medicare’s Part D prescription drug program.
• HLC Comments on The Lower Health Care Costs Act of 2019 Discussion Draft
• Letter to House Energy and Commerce Committee on “Investing in America’s Healthcare”
• Confidentiality Coalition comments in response to the Centers for Medicare and Medicaid Services’ Notice of Proposed Rulemaking on interoperability and patient access
• Confidentiality Coalition comments in response to the Office of the National Coordinator for Health Information Technology’s Notice of Proposed Rulemaking on interoperability and information blocking
• HLC comments in response to the Centers for Medicare and Medicaid Services’ Notice of Proposed Rulemaking on interoperability and patient access
• HLC comments in response to the Office of the National Coordinator for Health Information Technology’s Notice of Proposed Rulemaking on interoperability and information blocking

May 2019

• Letter to the Senate Special Committee on Aging hearing on “Aging and Disability in the 21st Century: How Technology Can Help Maintain Health and Quality of Life.”
• Friends of PCORI Reauthorization House Support Letter
• Friends of PCORI Reauthorization Senate Support Letter
• Letter to the House Budget Committee on Key Design Components and Considerations for Establishing a Single-Payer Health Care System
• Letter to the Senate Committee on the Judiciary hearing on “Intellectual property and the Price of Prescription Drugs, Focusing on Balancing Innovation and Competition.”
• Letter to the Senate Finance Committee hearing on “”Medicare Physician Payment Reform After Two Years, Focusing on Medicare Access and CHIP Reauthorization Act Implementation and the Road Ahead.”
• Confidentiality Coalition letter to the House Energy and Commerce Committee hearing on “Oversight of the Federal Trade Commission: Strengthening Protections for Americans’ Privacy and Data Security”
• RFI to CMS on Increasing consumer choice through the sale of individual health insurance coverage across state lines through healthcare choice compacts

April 2019

• Letter to House Rules Committee expressing concerns for H.R. 1384, Medicare-For-All Act of 2019
• Confidentiality Coalition letter to U.S. Senate in support of S. 1012 the “Protecting Jessica Grubb’s Legacy Act
• Confidentiality Coalition letter to U.S. House of Representatives in support of H.R. 2062 the “Overdose Prevention and Patient Safety Act
• HLC letter to the U.S. House in support of H.R. 2207, the “Protect Medical Innovation Act”
• HLC Letter to the U.S. Senate in support of S. 692, the “Protect Medical Innovation Act”
• HLC letter in support of S. 1012 the “Protecting Jessica Grubb’s Legacy Act”
• HLC letter in support of H.R. 2062 the “Overdose Prevention and Patient Safety Act”
• Group letter to HHS Inter-Agency Task Force on best practices in pain management
• HLC’s Comments to the Telehealth Request for Information in the 116^th Congress

March 2019

• Group letter to Congress in support for the Pandemic and All-Hazards Preparedness & Advancing Innovation Act (PAHPAI, H.R. 269). 
• HLC responds to Senator Warner’s request for answers on what healthcare entities are doing to protect patient information and essential operations from cyberattacks
• Letter responding to Senator Lamar Alexander’s request for recommendations to help address America’s rising healthcare costs
• Confidentiality Coalition letter to Senate Commerce Committee on Policy Principles for a Federal Data Privacy Framework in the United States
• Confidentiality Coalition letter to House Energy and Commerce Committee on Protecting Consumer Privacy in the Era of Big Data
• Letter to the House Energy and Commerce Committee on Lowering the Cost of Prescription Drugs Reducing Barriers to Market Competition
• Group letter to Congress in support of FY2020 NDPP Funding
• Group letter to Congress in support for Expanding Access to DSMT
• Letter to U.S. House of Representatives in support of H.R. 1398 to repeal the Health Insurance Tax
• Letter to Senate Committee on Aging on The Complex Web of Prescription Drug Prices
• Letter to Energy and Commerce Committee on Legislative ways to Strengthen Our Health Care System
• Response to the 2020 Medicare Advantage and Part D Advance Notice and Draft Call Letter
• Group letter to Senate Health, Education, Labor and Pensions (HELP) committee on reducing healthcare cost
• Group letter to CMS on recommendations to improve Medicare Diabetes Prevention Program (MDPP)
• Group sign on letter to HHS, Office of Disease Prevention and Health Promotion on Healthy People 2030

February 2019

• Group letter to Congress in support of the Special Diabetes Program
• Letter to Senator Cassidy and Senator Warner the on draft version of the Patient Affordability, Value and Efficiency Act
• Letter to Ways and Means Committee on The Cost of Rising Prescription Drug Prices
• Confidentiality Coalition letter in response to the HHS Office for Civil Rights’ HIPAA RFI
• Group Letter to the FDA on revisiting the 2008 CVOT Guidance
• HLC-BPC Interoperability Report – Advancing Interoperability, Information Sharing, and Data Access: Improving Health and Healthcare for Americans
• Letter to Senate Health, Education, Labor and Pensions Committee on the “Managing Pain During the Opioid Crisis” hearing.
• Letter to Education and Labor Committee on Examining Threats to Workers with Pre-existing Conditions

January 2019

• Letter to Ways and Means Committee on Protecting Pre-existing Conditions
• Letter to Senate Finance on Drug Pricing in America: A Prescription for Change, Part I
• Letter to House Oversight and Reform on Examining the Actions of Drug Companies in Raising Prescription Drug Prices
• Letter to U.S. Senators in support of S.172, The Health Insurance Tax Relief Act
• Letter to the ONC on the draft Strategy on Reducing Burden Relating to the Use of Health IT and EHRs
• Group letter in Support of Protecting Patient Access to Medication
• Confidentiality Coalition Letter in response to the National Institute of Standards and Technology’s RFI on Developing A National Privacy Framework
• Comment letter to the Centers for Medicare and Medicaid Services on the Medicare Advantage and Part D Flexibility Proposed Rule

December 2018

• Comment letter to the Department of Health and Human Services, and Centers for Medicare and Medicaid Services on the International Pricing Index Model for Part B Drugs.
• Letter to the Department of Homeland Security on Inadmissibility on Public Charge Grounds proposed rule
• Multistakeholder Letter urging Congress to Permanently Repeal the Medical Device Tax

November 2018

• Group letter in support of S. 3496, the Improving Seniors Access to Quality Benefits Act.
• Group letter in support of S. 3497, the Medicare Advantage Quality Payment Relief Act.
• Group letter to Senate Leadership urging them to bring the OPPS Act to the Senate floor for a vote during lameduck
• Better Medicare Alliance Group Letter Urging Delay of Health Insurance Tax through 2020
• Confidentiality Coalition Letter to Federal Communications Committee on modernizing the Telephone Consumer Protection Act
• Surgeon General’s Call to Action “Community Health and Prosperity” Comment Letter
• Confidentiality Coalition Letter in response to the National Telecommunications and Information Administration’s RFC on Developing the Administration’s Approach to Consumer Privacy

October 2018

• Letter in response to OIG RFI on Anti-Kickback Statute
• Confidentiality Coalition Letter to Senate Committee on Commerce, Science, and Transportation Hearing on Consumer Data Privacy
• Letter to Senate Committee on Aging on Patient-Focused Care: A Prescription to Reduce Health Care Costs
• Group Letter to Leadership in Support of Opioid Package Agreement

September 2018

• Letter to Senate Health, Education, Labor and Pensions (HELP) Committee on Health Care in Rural America: Examining Experiences and Costs
• Group Letter to House Leadership in Support of Opioid Package Agreement
• Group letter to Leadership urging inclusion of the Overdose Prevention and Patient Safety (OPPS) Act in a final opioid package
• Letter to U.S. Senators supporting their consideration of additional legislation addressing the nation’s opioid crisis
• Diabetes Advocacy Alliance Comments on the 2019 Medicare Physician Fee Schedule Proposed Rule

August 2018

• Letter in response to CMS RFI on Stark law
• Letter to Healthcare Innovation Caucus
• Group letter to Congress in Support of Value-Based Delivery and Payment Models
• Letter to House Energy and Commerce Committee on Examining State Efforts to Improve Transparency of Healthcare Costs for Consumers.

July 2018

• Letter to House Energy and Commerce Committee in support of markup of H.R. 6378
• Letter to Senate Health, Education, Labor and Pensions (HELP) Committee on Reducing Healthcare Costs: Decreasing Administrative Spending Hearing.
• Better Medicare Alliance Allies Letter in Support of H.R. 4952
• Group letter Urging Delay of the Health Insurance Tax Through 2020
• Letter to House Ways & Means Committee on Health Savings Account Mark-up
• Letter to HHS on the Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
• Letter in Response to HHS RFI on Healthcare Sector Innovation and Investment Workgroup
• Group letter to Senate Finance Committee on Access to Telehealth for Opioid Treatment
• Letter to House Ways and Means Committee on Stark Law Hearing

June 2018

• Group letter to CMS supporting expansion of Medicare Diabetes Prevention Program (MDPP)
• Group Letter in Support of U.S. House Legislative Efforts to Address Drug Crisis
• Letter on Consumer-Directed Health Plans Hearing
• Letter to the Joint Economic Committee on Health Savings Accounts
• Letter to House Energy and Commerce Committee on the Pandemic and All-Hazards Preparedness Act (PAHPA)
• Group Letter on Medicare Advantage Participation in Advanced Alternative Payment Models

May 2018

• Group letter to House and Senate Appropriations Committees on Patient Matching
• Obesity Care Advocacy Network Letter in Support of Nominations to the National Clinical Care Commission
• Letter to Senate Finance Committee on Rural Healthcare
• Letter on the Children’s Hospital Graduate Medical Education Program
• Letter to the Senate Health, Education, Labor, and Pensions Committee on the Healthcare Workforce
• Letter to House Energy and Commerce Committee on H.R. 5795, Overdose Prevention and Patient Safety (OPPS) Act
• Letter to House Ways and Means Committee on Health Innovation Hearing
• Group Letter to CMS on Virtual Diabetes Prevention Program in Medicare
• Letter to House Ways and Means Committee on the Medicare Advantage Hearing Letter to Senate Health, Education, Labor, and Pensions Committee on PAHPA Reauthorization
• Letter to House Energy and Commerce Committee on H.R. 3545, Overdose Prevention and Patient Safety (OPPS) Act

April 2018

• Patient Access to Pharmacists’ Care Coalition letter to the Energy & Commerce Committee on efforts to address the opioid epidemic
• Group Letter in Support of H.R. 4841 and Electronic Prior Authorization
• Confidentiality Coalition Letter on H.R. 4613, Ensuring Patient Access to Healthcare Records of 2017 – House Energy and Commerce Committee
• Confidentiality Coalition Letter on H.R. 4613, Ensuring Patient Access to Healthcare Records of 2017 – House Ways and Means Committee
• Confidentiality Coalition Letter on H.R. 4613, Ensuring Patient Access to Healthcare Records of 2017 – Senate HELP Committee

March 2018

• Diabetes Advocacy Alliance Letter to the Centers for Medicare and Medicaid Services on Diabetes Self-Management Training
• Letter on Price Transparency
• Obesity Care Advocacy Network Letter on US Preventive Services Task Force Obesity Recommendations
• HLC Letter to House Ways and Means Committee Hearing on the Implementation of MACRA’s Physician Payment Policies
• Letter to Medicaid and CHIP Payment and Access Commission on Substance Use Disorder Confidentiality Regulations and Care Integration in Medicaid
• Letter to US House of Representatives on 42 C.F.R. Part 2
• Letter to US Senate on 42 C.F.R. Part 2
• Group Letter on Individual Health Insurance Market Stabilization and Reinsurance
• Response to the 2019 Medicare Advantage and Part D Advance Notice and Draft Call Letter
• Letter on Reducing Red Tape in Medicare

February 2018

• Letter on OIG Solicitation of Safe Harbors
• Letters on the Preventive Health Savings Act
• Letter in Support of the State Offices of Rural Health Reauthorization Act
• Council for Affordable Health Coverage Letter on Health Insurance Market Stabilization
• Red Tape List of Reforms to Reduce Regulatory Burden
• Comment Letter on FDA’s New Strategic Policy Roadmap
• Letter on TEFCA Framework to ONC
• Letter in Support of the Medicaid Coverage for Addiction Recovery Expansion Act
• Letter in Support of the Good Samaritan Health Professionals Act
• Group Letter Urging Permanent Reauthorization of the Medicare Advantage Special Needs Plans
• Group Letter Urging Passage of Medicare Extenders Package

January 2018

• Letter to House Ways and Means Committee on the Opioid Crisis
• Letter to the Senate Health, Education, Labor, and Pensions Committee on Public Health Preparedness
• Response to the Department of Health and Human Services’ Request for Information on Promoting Choice and Competition Across the United States
• Letter Supporting Electronic Prior Authorization in Medicare Part D
• Letter to Senate Finance Committee on Health Savings Accounts
• Comments on the Proposed Policy Changes and Updates for the Medicare Advantage and Part D Prescription Drug Programs for 2019
• Letter Urging Repeal of the medical device tax and Health Insurance Tax
• Alex Azar Finance Committee letter

December 2017

• Group Letter Urging Extension of Safety Net Programs
• Letter to the House Ways and Means Committee on the Affordable Care Act’s Taxes and Mandates
• Coalition for Affordable Health Coverage Letter on the Senate Health, Education, Labor, and Pensions Committee Hearing on the Cost of Prescription Drugs
• Comments to the Food and Drug Administration on Regulatory Reform
• Group Thank You Letter on Funding for the Centers for Disease Control and Prevention

November 2017

• Letter in Support of the Preventive Health Savings Act
• Letter of Support for Alex Azar’s nomination as HHS Secretary (HELP Committee)
• HLC’s response to CMS’ Request for Information on the Center for Medicare and Medicaid Innovation
• Response to the 2019 Notice of Benefit and Payment Parameters
• Statement of Commitment to Clinician Well-Being and Resilience
• Letter to Senator Gardner on the Health Insurance Tax
• Letter to Senator Hatch on the Medical Device Tax
• Letter to Representative Paulsen on the Medical Device Tax
• Letter in Support of Legislation on the Section 1332 State Innovation Waivers
• Diabetes Advocacy Alliance Response to the Center for Medicare and Medicaid Innovation Request for Information
• Letter to Senate Health Education, Labor, and Pensions Committee on the Hearing on Healthy Communities

October 2017

• Coalition to Promote Independence in Medicare Letter in support of the Community-Based Independence for Seniors Act
• Obesity Care Advocacy Network Letter to the United States Pharmacopeia on the New Class for Anti-Obesity Agents
• Letter Urging the Inclusion of Telehealth Provisions in Upcoming Legislation
• Group Letter on the CHRONIC Care Act
• Diabetes Advocacy Alliance Comments on the Department of Health and Human Services Strategic Plan for 2018-2022
• Comments on the Department of Health and Human Services Strategic Plan for 2018-2022
• Comments to the Medicaid and CHIP Payment and Access Commission
• Letter in Support of S. 1978, the Small Business and Family Health Tax Relief Act
• Letter to Senate Health, Education, Labor, and Pensions Committee on the October 19 Wellness Hearing
• Letter to Acting Secretary Hargan on the National Clinical Care Commission Act
• Letter on the Community-Based Independence for Seniors Act
• Letter to Senator Gardner on the Health Insurance Tax Relief Act
• Letter to the Senate Finance Committee on the Children’s Health Insurance Program
• Letter to the House Energy and Commerce Committee on Public Health Programs

September 2017

• Stakeholder Comments to CMS on the Virtual Medicare Diabetes Prevention Program
• Letter to CMS on Concerns Related to Payment for Biosimilar Biological Products
• Campaign to End Obesity Action Fund Letter in Support of the Childhood Obesity Research Demonstration Program
• Stakeholder Letter to CMS Encouraging the Inclusion of Virtual Diabetes Prevention Program Providers
• Letter in Support of Delaying the Health Insurance Tax
• Letter on the Healthcare Workforce
• HLC Comments on W&M Medicare
• HLC Comments on E&C Health Subcommittee
• Diabetes Advocacy Alliance Letter on the Medicare Physician Fee Schedule and the Diabetes Prevention Program
• Diabetes Advocacy Alliance Letter on the Preventing Diabetes in Medicare Act
• Letter on Extending Safety Net Programs
• Letter to the Senate Finance Committee on the Children’s Health Insurance Program
• Letter to Senate Finance Committee on Health Reform
• Letter to Senate Health, Education, Labor, and Pensions Committee on Health Reform

August 2017

• Response to the Request for Information on Medicare Flexibility and Efficiency
• Letters to Senators Heller and Nelson on the Resident Physician Shortage Act
• HLC Comments on W&M Red Tape Initiative
• HLC Comments on CY18 QPP
• OPPS Act Letter of Support

July 2017

• Special Needs Plan Coalition Letter to Energy and Commerce Committee
• Letter to the House Ways and Means Committee On Its Markup of HR 3178 and HR 3168
• Letter in Support of the Nomination of Dr. Jerome Adams to be Surgeon General
• Letter in Support of the Patient Choice and Quality Care Act
• Letter to the Energy and Commerce Committee on the Medicare Advantage Special Needs Plans
• Diabetes Advocacy Alliance Letter on the Preventive Health Savings Act
• Letters in Support of the Personal Health Investment Today Act
• Response to the Department of Health and Human Services’ Request for Information on Reducing Regulatory Burdens Imposed by the Patient Protection and Affordable Care Act
• Diabetes Advocacy Alliance Letter on Funding for Diabetes Programs

June 2017

• Diabetes Advocacy Alliance Letter on the Medicare Diabetes Prevention Program
• Letter on the Alternative Payment Model Framework RefreshLetter on the State Children’s Health Insurance Program and the Federally Qualified Health Centers
• Letter to the Ways and Means Committee on Medicare Advantage
• Senate Health Reform Statement
• Medicaid Principles

May 2017

• Letter on Alternative Payment Models in Medicare Advantage
• Letter to Administrator Verma on Healthcare Common Procedure Coding System Codes
• Letter to Chairman of the Senate Committee on FinanceLetter to Representatives Crowley and Costello in Support of the Resident Physician Shortage Reduction Act
• Letter to Ways and Means Committee on Medicare Hearing
• Reforms to Regulations that will Improve Care Delivery and Lower Costs
• Letter on Medicare Advantage and Alternative Payment Models
• HLC Letter on the Medical Product Communications Act (H.R.1703)
• Letter in Support of CONNECT for Health Act

April 2017

• Letter to Senate HELP Committee Opposing Drug Importation
• Letter in Support of the National Clinical Care Commission Act
• Letter to Congressional Leadership on the Cost Sharing Reduction Subsidies
• Letter in Response to the Medicare Transformative Ideas Request for Information
• Letter in support of the CHRONIC Care Act
• Letter to Secretary Price on Market Stabilization
• FY1718 Labor-H Patient Matching Report Langauge Support Letter v FINAL

March 2017

• Letter on Education and Workforce March 1 hearing
• Comments on the Lower Drug Costs through Competition Act
• Medicare Advantage Call Letter Response
• Letter on the Market Stabilization Rule
• Letter to Chairman Walden and Chairman Brady on the AHCA
• Diabetes Advocacy Alliance Letter to Secretary Price
• Diabetes Advocacy Alliance Letter in support of National Diabetes Prevention Program funding

February 2017

• National Osteoporosis Foundation Letter on Non Interference
• Partnership for Safe Medicines letter to Congress
• Judiciary Protecting Access to Care Act
• Protect Patient Access to Medication Group Letter on Non-Interference
• SAMHSA SNPRM Rule Partnership Comments
• Group Letter in Support of IPAB Repeal
• Letter of Support for Seema Verma’s nomination as CMS Administrator
• Letter of Support for the Saving Lives, Saving Costs Act of 2017
• Letter to Small Business Committee on their Healthcare Hearing February 7
• Letter to Energy and Commerce Committee on exchanges
• Letter to Health, Education, Labor, and Pensions Committee on stabilizing the individual market

January 2017

• Comments to the National Quality Forum on the African American Heart Failure eMeasure 2764
• Comments to the National Quality Forum on African American Heart Failure Measure MUC 16-74
• Jan 25 Value Letter-Administration
• Letter on the Pharmaceutical Information Exchange (PIE) Act of 2017
• Letter to Ways and Means Committee on individual mandate hearing
• Letter of Support for Rep. Price’s nomination as HHS Secretary (Finance)
• Letter of Support for Rep. Price’s nomination as HHS Secretary
• Group Letter on Medicare Non-Interference & Importation

December 2016

• Letter to New Administration
• HLC Playbook “Better Healthcare for All Americans:  A Proposed Agenda”